Icon
+91 94997 68112
Login Register

KOSELUGO - (10MG, 25MG)

SELUMETINIB SULFATE None
10MG, 25MG
Less Than $1000 mn
None None
None None
None None
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Yes
KOSELUGO Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
*** *********

KOSELUGO - (10MG, 25MG)

SELUMETINIB SULFATE None
10MG, 25MG
Less Than $1000 mn
None None
None None
None None
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Yes
KOSELUGO Patent 1 Patent 2 Patent 3 Patent 4
*** *********

KOSELUGO - (5MG, 7.5MG)

SELUMETINIB SULFATE None
5MG, 7.5MG
Less Than $1000 mn
None None
None None
None None
KOSELUGO is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
Yes
KOSELUGO Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.